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Abstract
Studies in mutant, gene knock-out and transgenic mice have demonstrated that growth hormone (GH) signalling has a major impact on 
ageing and longevity. Growth hormone-resistant and GH-deficient animals live much longer than their normal siblings, while transgenic 
mice overexpressing GH are short lived. Actions of GH in juvenile animals appear to be particularly important for life extension and 
responsible for various phenotypic characteristics of long-lived hypopituitary mutants.
Available evidence indicates that reduced GH signalling is linked to extended longevity by multiple interacting mechanisms including 
increased stress resistance, reduced growth, altered profiles of cytokines produced by the adipose tissue, and various metabolic adjust-
ments such as enhanced insulin sensitivity, increased oxygen consumption (VO2/g) and reduced respiratory quotient. The effects of remov-
ing visceral fat indicate that increased levels of adiponectin and reduced levels of pro-inflammatory cytokines in GH-resistant mice are 
responsible for their increased insulin sensitivity. Increased VO2 apparently represents increased energy expenditure for thermogenesis, 
because VO2 of mutant and normal mice does not differ at thermoneutral temperature. Recent studies identified GH- and IGF-1-dependent 
maintenance of bone marrow populations of very small embryonic-like stem cells (VSELs) as another likely mechanism of delayed ageing 
and increased longevity of GH-deficient and GH-resistant animals.
Many of the physiological characteristics of long-lived, GH-related mouse mutants are shared by exceptionally long-lived people and by 
individuals genetically predisposed to longevity. (Endokrynol Pol 2013; 64 (1): 46–52)
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Streszczenie
W badaniach na zmutowanych i transgenicznych myszach wykazano, że przekazywanie sygnałów przez hormon wzrostu (GH) wywiera 
istotny wpływ na procesy starzenia się organizmu i długowieczność. Zwierzęta, u których stwierdza się oporność na hormon wzrostu 
lub jego niedobór, żyją dłużej niż ich normalne rodzeństwo, podczas gdy myszy transgeniczne wykazujące nadekspresję GH żyją krótko. 
Działania, jakie wywiera GH u młodocianych zwierząt wydają się odgrywać szczególnie ważną rolę w wydłużaniu życia i są odpowie-
dzialne za różnorodne cechy fenotypowe długowiecznych mutantów z niedoczynnością przysadki.
Z dostępnych dowodów naukowych wynika, że osłabione przekazywanie sygnałów przez GH wiąże się ze zwiększeniem długowieczności, 
u podstawy czego leży wiele współzależnych mechanizmów obejmujących zwiększoną odporność na stres, osłabione wzrastanie, zmie-
niony profil cytokin wytwarzanych przez tkankę tłuszczową, a także różne adaptacje metaboliczne, np. zwiększona insulinowrażliwość, 
zwiększone zużycie tlenu (VO2/g) i zmniejszony współczynnik oddechowy. Konsekwencje usunięcia trzewnej tkanki tłuszczowej wskazują, 
i że zwiększoną insulinowrażliwość u myszy opornych na GH odpowiedzialne jest zwiększone stężenie adyponektyny i zmniejszone 
stężenie cytokin prozapalnych. Zwiększone VO2 wydaje się wynikać ze zwiększenia wydatkowania energii na termogenezę, bowiem 
w temperaturze termoneutralnej VO2 u myszy zmutowanych i myszy niezmutowanych nie różni się. W najnowszych badaniach — jako 
kolejny prawdopodobny mechanizm opóźnionego starzenia się organizmu i zwiększonej długowieczności u zwierząt z niedoborem GH 
i opornością na GH — zidentyfikowano zależne od GH i IGF1 podtrzymywanie szpikowych populacji bardzo małych komórek macie-
rzystych podobnych do zarodkowych (VSEL, very small embryonic-like stem cells).
Wiele z cech fizjologicznych długowiecznych myszy z mutacjami związanymi z GH występuje też u bardzo długo żyjących ludzi i osób 
genetycznie predysponowanych do długowieczności. (Endokrynol Pol 2013; 64 (1): 46–52)
Słowa kluczowe: hormon wzrostu (GH), ograniczenie kaloryczne, insulinopodobny czynnik wzrostu 1 (IGF1), myszy karłowate szczepu Ames, 
myszy z wyłączonym genem kodującym receptor hormonu wzrostu (GHRKO)
Introduction
In laboratory populations of house mice (Mus musculus), 
the strength of growth hormone (GH) signals is a ma-
jor determinant of ageing and longevity. In transgenic 
mice expressing various GH genes under the control of 
metallothionein or phosphoenolpyruvate carboxykin-
ase promoters, massive overproduction of GH leads 
to drastically reduced lifespan and many symptoms 
of accelerated ageing [1]. In contrast, GH deficiency in 
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hypopituitary mutants and GH resistance in mice with 
targeted deletion of GH receptors are associated with 
approximately 30%–60% lifespan extension, depending 
on the mutation involved, genetic background, sex and 
diet composition [2–5]. Importantly, GH-deficient and 
GH-resistant mice exhibit many symptoms of delayed 
ageing and have an extended ‘health span’ i.e. a period 
of life free from major disease or functional impairments 
[3, 5, 6].
The incidence of fatal neoplastic disease is reduced, 
and its onset delayed, in these long-lived GH-related 
mutants [7–9]. Studies of the phenotypes of these 
mutant animals have revealed partial overlap with the 
characteristics of genetically normal mice subjected 
to long-term calorie restriction (CR; a life-extending 
intervention) and identified a number of very likely 
(although at this time not conclusively proven) candi-
date mechanisms of their delayed ageing and extended 
longevity. These mechanisms include enhanced activity 
of antioxidant enzymes and reduced oxidative damage 
[10, 11]; increased cellular resistance to a variety of toxic 
substances and stressful conditions [12, 13]; reduced 
activity of a nutrient-sensing mammalian target of 
rapamycin (mTOR) pathway that regulates translation 
and growth [14, 15]; and improved sensitivity to insulin 
coexisting with reduced insulin levels [15–17]. Impor-
tantly, negative association of GH action with longevity 
discovered in mutant, gene knock-out and transgenic 
mice also applies to genetically normal (‘wild-type’) ani-
mals. Comparisons of mice from different strains, as well 
as individual animals from a genetically heterogeneous 
normal population, has revealed that smaller animals 
live longer [18, 19], and circulating levels of insulin-like 
growth factor 1 (IGF-1, the key mediator of GH stimula-
tory action on somatic growth) are negatively correlated 
with longevity [19, 20].
The ground-breaking discovery of significant ho-
mology of longevity genes of a tiny, free-living worm, 
Caenorhabditis elegans, with mammalian genes involved 
in insulin and IGF-1 signalling [21, 22] led to identifi-
cation of a conserved pathway of endocrine signal-
ling that controls ageing and longevity in organisms 
ranging from yeast to mammals [23, 24]. This pathway 
comprises multiple insulin-like and IGF-like hormones 
in worms and insects, insulin and IGF in vertebrates, 
the corresponding receptors (one in worms and insects 
but several in invertebrates) as well as their signalling 
intermediates including insulin receptor substrates, 
phospatidylinositol kinase, protein kinase B (Akt) and 
an important FOXO family of transcription factors 
that indirectly control cellular defences from oxidative 
stress along with other functions. In mammals, GH is 
intimately involved in the functioning of this pathway 
by serving as the key determinant of hepatic IGF-1 
expression and circulating IGF-1 levels. It also acts as 
a counter-regulatory hormone in carbohydrate ho-
meostasis by promoting insulin resistance and exerting 
various anti-insulinaemic effects.
While pathological excess of GH secretion reduces 
life expectancy in people as it does in mice [1, 25], the 
impact of hypopituitarism, GH deficiency and GH 
resistance on human longevity is poorly understood, 
controversial and probably relatively minor [26–28]. 
However, individuals with genetic GH deficiency or GH 
resistance are remarkably, and in some cases apparently 
completely, protected from major age-related diseases 
including atherosclerosis, diabetes and, most strikingly, 
cancer [26, 27, 29–31].
In this article, we will briefly review and discuss 
some recent findings in GH-deficient and GH-resistant 
mice that identify novel candidate mechanisms of their 
extended longevity and raise new questions about re-
lationships between somatotropic (GH;IGF) signalling 
and ageing.
Energy metabolism and role of ambient 
(environmental) temperature
Indirect calorimetry studies have revealed that in both 
hypopituitary Ames dwarf (Prop1df) and insulin-
resistant GH receptor-deleted (GHRKO) mice, oxygen 
consumption (VO2) per gram of body weight is in-
creased during both active (dark) and resting (light) 
portions of the 24 h period [32]. These differences were 
evident regardless of the presence or absence of food 
during recording and were accompanied by a reduction 
in respiratory quotient (RQ) [32]. Respiratory quotient 
represents ratio of carbon dioxide produced to oxygen 
consumed and provides an estimate of the relative 
amounts of carbohydrate vs. lipids (primarily fatty 
acids) utilised as energy substrates.
The finding that long-lived dwarf mice have in-
creased metabolic rate (as assessed by VO2) was counter-
intuitive and contrary to our expectations because these 
animals have reduced levels of anabolic and thermogen-
ic hormones, GH, IGF-1 and insulin. Ames dwarf mice 
are also severely hypothyroid. However, the observed 
differences were relatively large and reproducible, and 
apparently did not represent an artifact of the fact that 
this data was expressed per unit of body mass rather 
than per unit of calculated lean or ‘metabolic’ body 
mass. Estimates of lean body mass are based on the as-
sumption that smaller animals are proportionally leaner, 
while the amount of adipose tissue in these mutants 
is either increased or nearly normal (depending on 
the mutation, sex and age) [33–35]. When we re-calcu-
lated VO2 data in GHRKO and normal mice in terms of 
the actual percent of lean body mass as determined by 
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dual energy X-ray absorptiometry (DEXA), the increase 
of VO2 in the mutants not only persisted but became 
exaggerated [Westbrook and Bartke, unpublished].
In small animals maintained in a standard animal 
room temperature (approx. 23oC), a considerable pro-
portion of the energy budget is devoted to thermo-
genesis. Consequently, we suspected that the increase 
in VO2 in dwarf mice may reflect increased energy 
demand for compensation for the increased heat loss 
by radiation in these diminutive animals. This com-
pensation would allow them to maintain stable body 
temperature. To test the validity of this hypothesis, we 
repeated indirect calorimetry studies in GHRKO and 
normal mice at a thermoneutral temperature, which 
in mice is approximately 30oC. In the thermoneutral 
environment, the metabolic rate decreased as expected, 
but this decrease was incomparably greater in GHRKO 
than in normal mice. As a result, the difference in VO2 
between the normal and mutant animals disappeared 
[Westbrook and Bartke, unpublished]. It is tempting to 
speculate that, at a standard animal room temperature, 
increased thermogenesis in dwarf mice leads to greater 
utilisation of lipids as an energy source (‘fat burning’) 
and more efficient function of mitochondria with re-
duced production of reactive oxygen species, and that 
these metabolic adaptations contribute to the extended 
longevity of these animals. In support of these specula-
tions, similar metabolic adaptations develop in response 
to calorie restriction, and some of the beneficial effects of 
calorie restriction were reported to be attenuated if the 
mice were housed at a thermoneutral temperature [36]. 
Inflammation; secretory activity  
of adipose tissue
There is considerable, although largely only correlative, 
evidence that inflammatory processes and circulating 
inflammation markers are involved in the control of 
human ageing, age-related disease and longevity [37, 
38]. Growth hormone has been reported to exert both 
anti- and pro-inflammatory effects [39-41], while inflam-
mation can influence GH release and actions [42, 43]. 
Available information indicates that the expression as 
well as tissue and blood levels of pro-inflammatory cy-
tokines, interleukin 6 (IL-6) and tumour necrosis factor 
alpha (TNF-a) are reduced in long-lived GH-deficient 
and GH-resistant mice [44, 45]. Moreover, circulating 
levels of an anti-inflammatory adipokine, adiponectin, 
are consistently elevated in these animals [15, 45]. This 
latter observation was unexpected because the absence 
of GH signals in these mutants leads to increased 
adiposity, and because, in both laboratory animals and 
humans, plasma levels of adiponectin have been repeat-
edly shown to be inversely rather than directly related 
to adiposity. Thus, circulating adiponectin levels are 
normally reduced in obese individuals, while leanness 
and calorie restriction are associated with increased 
plasma adiponectin. Apparently, in Ames dwarf and 
in GHRKO mice, absence of GH action overrides the 
influence of increased adiposity on adiponectin secre-
tion. In support of this interpretation, over-expressing 
GH adiposity in transgenic mice is reduced, and yet 
adiponectin levels are reduced rather than elevated [46].
Because adiponectin promotes insulin sensitivity, in-
creased adiponectin levels in GHRKO and Ames dwarf 
mice are consistent with improved insulin signalling 
in these animals, and indeed provide a very plausible 
explanation as to why these generally obese animals are 
insulin sensitive rather than insulin resistant. It is also 
likely that the anti-inflammatory and anti-atherogenic 
activity of adiponectin contribute to the extension of 
health span and lifespan in these mutants.
Recent studies involving surgical removal of visceral 
adipose tissue have provided strong support for the 
suspected role of increased adiponectin levels in the 
enhancement of insulin sensitivity in GHRKO mice. 
Visceral fat is an important source of cytokines, and in 
obese individuals it is believed to be involved in produc-
ing a state of chronic, low-grade inflammation leading 
to insulin resistance and increased risk of age-related 
disease. Consistent with this role of visceral fat in glu-
cose homeostasis and ageing, surgical removal of most 
of the abdominal fat from male rats resulted in improved 
insulin sensitivity and a significant extension of lifespan 
[46]. To address the paradox of the coexistence of obesity 
and enhanced insulin sensitivity in GHRKO mice, we 
compared the effects of removing visceral (epididymal 
and perinephric) fat in GHRKO and normal mice. In 
normal animals, visceral fat removal improved insulin 
sensitivity (measured by insulin tolerance tests, ITT) and 
clearance of injected glucose (measured in glucose toler-
ance tests, GTT), as anticipated. In contrast, in GHRKO 
mice, the same surgical procedure led to a reduction of 
plasma adiponectin levels and deterioration of glucose 
homeostasis as measured by ITT and GTT [47].
Studies of epididymal fat pads confirmed increased 
expression of adiponectin and reduced expression of 
interleukin 6 (IL-6) in GHRKO compared to normal 
mice [47]. It can be concluded that, in the absence of 
GH signals, the secretory profile of adipose tissue (or 
perhaps, specifically, intraabdominal adipose tissue) is 
shifted from pro-inflammatory to anti-inflammatory 
adipokines. This shift importantly contributes to para-
doxically improved insulin signalling in obese GHRKO 
males. Together with the documented anti-atherogenic 
actions of adiponectin, these changes probably contrib-
ute to the extension of longevity in GHRKO mice. Stud-
ies of gene expression in peripheral blood leukocytes 
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in Ames dwarf mice have indicated that activation of 
anti-inflammatory pathways in long-lived GH-related 
mutants extends beyond the adipose tissue [48].
Intriguingly, some of the interactions between in-
flammatory processes and metabolism demonstrated 
in mutant mice appear to also apply to humans. In 
humans, as in mice, the absence of GH signals leads to 
obesity, which is strongly associated with insulin resist-
ance and increased risk of chronic disease. However, 
hereditary GH resistance in an extensively studied pop-
ulation of individuals with Laron dwarfism in Ecuador 
was associated with striking, nearly complete, protec-
tion from cancer and diabetes [27]. Moreover, a cohort 
of GH-deficient dwarfs studied in Brazil was shown to 
be unexpectedly protected from atherosclerosis in spite 
of obesity and unfavourable serum lipid profiles [26].
Maintenance of bone marrow populations 
of pluripotent stem cells
Although the role of stem cells in the control of longevity 
and protection from age-related disease remains to be 
fully elucidated, there is considerable evidence for their 
involvement in the maintenance and repair of adult 
tissues [49–52]. A population of pluripotent very small 
embryonic-like stem cells (VSELs) in the bone marrow 
has been identified on the basis of a unique combination 
of markers and ability to differentiate into a wide vari-
ety of cell types in vitro [53–57]. It has been postulated 
that these developmentally primitive cells are dormant 
precursors of more restricted tissue-committed stem 
cells, and thus play a role in steady state conditions 
in tissue organ rejuvenation and regeneration after 
injury [57]. In mice, the number of VSELs in the bone 
marrow declines with age [58], and their maintenance 
has been linked to the control of methylation state of 
a number of imprinted genes related to IGF signalling 
[59]. It was therefore interesting to assess the abundance 
of VSELs in GH-related mutants in which circulating 
levels of IGF-1 are dramatically suppressed. Results of 
these studies revealed that the numbers of VSELs are 
greater in Ames dwarf and GHRKO mice than in normal 
animals from the same strains [60, 61 and unpublished 
observations]. These differences were large, with little 
or no overlap between the values measured in mutant 
and normal animals, and were present in both young 
adult and middle-aged mice [60, 61 and unpublished 
observations]. In interesting contrast, the number of 
VSELs was reduced in GH transgenic mice in which 
circulating IGF-1 levels are chronically elevated [62]. 
Hormonal replacement therapy with GH in Ames 
dwarf mice and with IGF-1 in GHRKO animals, as well 
as treatment of normal mice with large doses of GH, 
reduced the number of VSELs in their bone marrow 
[61]. These results clearly establish that in animals with 
GH deficiency or GH resistance and the consequent 
suppression of plasma IGF-1 levels, the abundance of 
VSELs in the bone marrow is increased, probably reflect-
ing reduced differentiation and/or other mechanisms of 
age-dependent depletion.
In the same studies, the effects of altered GH levels or 
actions on the number of haematopoietic stem cells were 
generally parallel to the above-described impact on the 
number of VSELs [60–62]. It is interesting to speculate 
that the observed relationships between the activity 
of the somatotropic axis and the populations of VSELs 
may apply more broadly, and include various categories 
of stem and progenitor cells. This in turn could prove 
important for the repair and maintenance of different 
tissues and organs and thus may represent yet another 
mechanism that links reduced GH/IGF-1 signalling with 
the extension of health span and lifespan.
Impact of prepubertal GH signalling  
on longevity
Failure of somatotroph differentiation and the resulting 
GH deficiency in Ames (Prop1-df) and Snell (Pit1-dw) 
mice led to dramatic reductions in the rate of postnatal 
growth and adult body size. These mutants are also 
thyroid-stimulating hormone (TSH) and prolactin (PRL) 
deficient [51]. The effects of treating dwarf mice with 
thyroxine (T4) or PRL indicate that hypothyroidism re-
sulting from TSH deficiency contributes to the reduced 
growth and adult size of these animals. The role of 
PRL deficiency in reduced growth of these mutants is 
less clear and almost certainly minor. The unexpected 
remarkable increase of longevity of both Ames and Snell 
dwarf mice, as well as in other GH-related mutants, 
raised a question of the possible significance of the rate 
of postnatal growth in the determination of lifespan. 
The fact that the negative correlation of longevity with 
adult body size detected in mutant, gene knock-out 
and transgenic mice also applies to genetically normal 
mice [18, 19], domestic dogs [55] and other species [56, 
57] provided additional rationale for probing the role 
of post-natal growth in the determination of longevity. 
Studies conducted in the Miller laboratory in Snell 
dwarf mice [58], as well as our initial studies in Ames 
dwarfs, demonstrated that treatment of juvenile dwarf 
mice with GH, T4 or a combination of GH and T4 pro-
duced the expected increase in body weight and length. 
Longevity, however, was not affected. In these studies, 
Snell dwarfs were given hormonal treatments between 
four and 15 weeks of age, while Ames dwarf mice were 
injected with GH (once daily), T4 (three times per week) 
or both starting at two weeks of age and continuing 
for six weeks. In a follow-up study, we have increased 
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the dose of GH as well as the frequency of injections 
(twice a day on weekdays and once a day on weekends) 
and observed a major reduction in the longevity of 
GH-treated Ames dwarf mice [59]. During the period 
of GH treatment, these animals grew at a rate roughly 
comparable to the growth of normal mice; but when 
the treatment was stopped, their growth rate levelled 
off and their adult body size was intermediate between 
the size of normal mice and control (vehicle-injected) 
dwarfs. Thus, it would appear that GH signalling dur-
ing the normally rapid early (prepubertal) growth has 
an important role in the determination of ageing and 
lifespan. Preliminary data derived from recent and 
ongoing studies in our laboratory suggests that this 
’critical period’ of the action of GH on lifespan begins 
fairly early (during the period of suckling), and there 
are some intriguing indications that it may be advanced 
and/or shortened by treatment with T4 [Spong and 
Bartke, unpublished]. 
The importance of early ‘developmental’ effects of 
GH in the determination of lifespan was not expected 
because GH is believed to have a very limited role, if any, 
in the control of pre-weaning growth in rodents [60]. 
However, the involvement of early postnatal events in 
the determination of longevity received strong support 
from the recent demonstration in the Miller labora-
tory that reducing pre-weaning growth in genetically 
normal mice by increasing the number of pups suckled 
by one female significantly extends their average and 
maximal lifespan [61].
Working with dwarf rats, which have reduced soma-
totropic signalling but normal lifespan, Sonntag et al. 
reported that twice-daily injections of GH between the 
ages of four and 14 weeks led to a significant increase 
in longevity [62]. 
 Although more work is obviously needed to fully 
reconcile findings in different species and in long-lived 
mutants vs. normal animals, it appears to be justified 
to conclude that ageing and lifespan are significantly 
related to early postnatal growth and to the actions 
of GH during this period. This might appear counter-
intuitive, but is not surprising when viewed in the light 
of the well-documented early (‘organisational’) effects 
of steroid hormones on reproductive behaviour, fertil-
ity and responses to stress. Moreover, there is rapidly 
accumulating evidence for the important impact of 
early, nutrition-related ‘developmental programming’ 
on adult metabolism and susceptibility to chronic 
disease [63, 64].
We are currently searching for mechanisms that 
may link GH actions in juvenile animals with ageing 
and longevity. As the initial step, we are interested in 
identifying longevity-related traits that are influenced 
by early GH therapy and remain altered after GH treat-
ment is stopped. The most recent data suggests that 
GH-induced insulin resistance is not a likely mechanism 
of shortened lifespan in GH-injected dwarfs. However, 
increased oxygen consumption per unit body mass 
(VO2/g) and reduced respiratory quotient (RQ), which 
we have previously identified as metabolic character-
istics of Ames dwarf and GHRKO mice [32], were com-
pletely (VO2) or partially (RQ) normalised (‘rescued’) 
in GH-injected dwarfs five months after completion 
of GH therapy [Westbrook and Bartke, unpublished]. 
Adult hepatic expression of genes coding for several 
detoxification enzymes was also normalised by treat-
ment of Ames dwarf mice with GH between two and 
eight weeks of age [Sun and Bartke, unpublished]. In 
as much as improved mitochondrial function, increased 
utilisation of fatty acids for energy metabolism (as 
indicated by reduced RQ), and improved breakdown 
(detoxification) of xenobiotics are probable contributors 
to the extended longevity of Ames dwarf versus normal 
mice, the elimination or suppression of these character-
istics in GH-injected dwarfs may represent candidate 
mechanisms of reduced life expectancy.
Conclusion
Studies in mutant, gene knock-out and transgenic ani-
mals with extreme, well-defined, hereditary alterations 
in somatotropic signalling have revealed a prominent 
role of GH in the control of mammalian ageing and 
identified multiple interactive mechanisms that appear 
to be responsible for these relationships. It is hoped 
that further studies in these animals will help clarify 
the mechanisms by which GH influences ageing and 
elucidate the role of variations in the somatotropic axis 
activity within the normal (physiological) range in the 
control of ageing in genetically normal (‘wild-type’) 
animals and in humans. 
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